Results 61 to 70 of about 9,645 (157)

CRISPR Technology in Disease Management: An Updated Review of Clinical Translation and Therapeutic Potential

Cell Proliferation, EarlyView.
CRISPR‐Cas systems offer transformative genome editing capabilities for precise manipulation of cellular genes. This enables two main therapeutic avenues: ex vivo modification of patient cells for re‐transplantation or direct in vivo gene targeting via advanced delivery methods.
Bahareh Farasati Far, Marziyeh Akbari, Mohammad Amin Habibi, Morteza Katavand, Sherko Nasseri   +4 more
wiley   +1 more source

Differential Signaling through p190 and p210 Forms of BCR-ABL Fusion Proteins Revealed By Proteomic Analysis

Blood, 2015
Abstract Chromosomal translocations involving chromosome 9q34 and 22q11 generate the BCR-ABL1 fusion gene. The location of the translocation within the BCR gene dictates which exons are excluded or included in the resulting fusion with the ABL1 gene.
Rahia Tahir, Saradhi Mallampati, Akhilesh Pandey, Xiaoping Sun, Patrick Brown, Jingnan Han, Xianrong Wong, Karen L. Reddy, Jevon Cutler, Tai-Chung Huang, Raja Sekhar Nirujogi   +10 more
openaire   +2 more sources

Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes [PDF]

Leukemia, 2002
Although CD4(+) helper T lymphocytes have been demonstrated to play an important role in antitumor immune response, only a few epitopes of tumor-associated antigens recognized by HLA class II-restricted CD4(+) T lymphocytes have been identified.
Shigeru Fujita, Masaki Yasukawa, Kensuke Kojima, Mine Harada, Mitsune Tanimoto, H Hamaguchi, Masanori Makita, Hironari Niiya, Taichi Azuma   +8 more
openaire   +2 more sources

Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity [PDF]

, 2015
Clinical effectiveness of imatinib mesylate in cancer treatment is compromised by its off-target cardiotoxicity. In the present study, we have developed physically stable imatinib mesylate-loaded poly(lactide-co-glycolide) nanoparticles (INPs) that could
Balakumar, Krishnamoorthy, Franklin, Gregory, Khandelwal, Vinoth Kumar Megraj, Marslin, Gregory, Prakash, Jose, Revina, Ann Mary, Sheeba, Caroline Jeya   +6 more
core   +2 more sources

A computational dynamic model of combination treatment for type II inhibitors with asciminib

Protein Science, Volume 34, Issue 8, August 2025.
Abstract Despite continuous strides forward in drug development, resistance to treatment looms large in the battle against cancer as well as communicable diseases. Chronic myeloid leukemia (CML) is treated with targeted therapy and treatment is personalized when resistance arises.
J. Roadnight Sheehan, Astrid S. de Wijn, Ran Friedman   +2 more
wiley   +1 more source

The Functional Interplay Between the t(9;22)-Associated Fusion Proteins BCR/ABL and ABL/BCR in Philadelphia Chromosome Positive Acute Lymphatic Leukemia [PDF]

Blood, 2014
Abstract The successful targeting of BCR/ABL by selective ABL-kinase inhibitors (AKI) such as Imatinib, Nilotinib, or Dasatinib alone is unable to eradicate the leukemic clone in Philadelphia chromosome positive (Ph+ ) leukemia. The t(9;22)(q34;q11) is a balanced translocation.
Anahita Rafiei, Oliver G. Ottmann, Claudia Oancea, Martin Ruthardt, Afsar Ali Mian   +4 more
openaire   +2 more sources

Computational and mechanistic studies on the effect of galactoxyloglucan: Imatinib nanoconjugate in imatinib resistant K562 cells

Tumor Biology, 2017
Imatinib mesylate, a BCR/ABL fusion protein inhibitor, is the first-line treatment against chronic myelogenous leukemia. In spite of its advantageous viewpoints, imatinib still has genuine impediments like undesirable side effects and tumor resistance ...
Alphy Rose James, BS Unnikrishnan, R Priya, Manu M Joseph, TK Manojkumar, K Raveendran Pillai, R Shiji, GU Preethi, P Kusumakumary, TT Sreelekha   +9 more
doaj   +1 more source

Perturbation of Methionine/S-adenosylmethionine Metabolism as a Novel Vulnerability in MLL Rearranged Leukemia

Cells, 2019
Leukemias bearing mixed lineage leukemia (MLL) rearrangement (MLL-R) resulting in expression of oncogenic MLL fusion proteins (MLL-FPs) represent an especially aggressive disease subtype with the worst overall prognoses and chemotherapeutic response. MLL-
Aditya Barve, Alexis Vega, Parag P. Shah, Smita Ghare, Lavona Casson, Mark Wunderlich, Leah J. Siskind, Levi J. Beverly   +7 more
doaj   +1 more source

Molecular mechanisms in haematological malignancies [PDF]

, 2009
Haematopoiesis requires the constant production of large numbers of peripheral blood cells. This process is under tight control of transcription factor networks as well as cytokines, growth factors and hormones.
Avellino, Roberto, Grech, Godfrey, Schembri-Wismayer, Pierre   +2 more
core  

MTSS1 is a critical epigenetically regulated tumor suppressor in CML [PDF]

, 2015
Chronic myeloid leukemia (CML) is driven by malignant stem cells that can persist despite therapy. We have identified Metastasis suppressor 1 (Mtss1/MIM) to be downregulated in hematopoietic stem and progenitor cells from leukemic transgenic SCLtTA/Bcr ...
Braunschweig, T., Brümmendorf, T. H., Chatain, N., Copland, M., Costa, I. G., Gusmao, E. G., Haenzelmann, S., Hamilton, A., Helgason, G.V., Herrmann, O., Holyoake, T. L., Kintsler, S., Koschmieder, S., Li, S., Merle Reher, M., Müller-Tidow, C., Schemionek, M., Schubert, C., Schwab, A.   +18 more
core   +1 more source